Form 4: Inhibikase Therapeutics Insider Reports Stock Transaction
Insider Transaction (Form 4)
Ra Capital Management, L.P. and 3 others reported changes in beneficial ownership of Inhibikase Therapeutics, Inc. common stock on July 29, 2026.
Summary
- Other acquisition/disposition: disposed of 18,030,000 Common Stock on July 29, 2026; holds 6,970,000 after (Indirect).
- Other acquisition/disposition: acquired 18,030,000 Pre-Funded Warrant (Right to Buy) on July 29, 2026; holds 18,030,000 after (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ra Capital Management, L.P. — 10% owner
RA Capital Healthcare Fund LP — 10% owner
Peter Kolchinsky — 10% owner
Rajeev M. Shah — 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-29 | Other acquisition/disposition | Common Stock | 18,030,000 | — | — | 6,970,000 |
| 2026-07-29 | Other acquisition/disposition | Pre-Funded Warrant (Right to Buy) | 18,030,000 | — | — | 18,030,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-29 | Other acquisition/disposition (18,030,000 shares) |
| 2026-07-29 | Other acquisition/disposition (18,030,000 shares) |
Keywords
insider transaction, Form 4, IKT, Inhibikase Therapeutics, Inc., neutral, Ra Capital Management, L.P., RA Capital Healthcare Fund LP, Peter Kolchinsky, Rajeev M. Shah
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.